CHOP is recruiting research participants for a new observational study called, “DISCOVERY of Risk Factors for Type 2 Diabetes in Youth,” led by Lorraine L. Katz, MD.

Tzield, the first FDA-approved treatment to delay the onset of clinical diabetes, is now available in the Type 1 Diabetes clinic at CHOP

Learn more about how genetic testing offers the best means of distinguishing between the focal and diffuse forms of HI in children.

Researchers at Children’s Hospital of Philadelphia (CHOP) announced the launch of the initial phase of DISCOVERY of Risk Factors for Type 2 Diabetes in Youth, a nationwide National Institute of Health (NIH) study to address the surge in youth diagnosed with type 2 diabetes over the past two decades.

The Diabetes Center at CHOP aims to diminish persistent racial disparities in diabetes care by involving families, tracking treatment, follow-up care and device use, and revealing individuals’ implicit biases.  

Experts in the STRIVE Program work collaboratively to delivery comprehensive care to children with differences in sexual development/intersex and other conditions.

When initial lab results for a child with hypoglycemic didn’t make sense, we measured her insulin by liquid chromatography-mass spectrometry. What did we learn?

CHOP’s HI Center, a Frontier Program, continues to set the standard for caring for children with congenital hyperinsulinism.

The 2023 Congenital Hyperinsulinism Family Conference, held at CHOP in April, was a roaring success, with more than 225 attendees.

New pediatric endocrinologist Julia Crowley, MD, will see children in CHOP’s Congenital Hyperinsulinism Center. Meet her in this Q&A. [short teaser] Meet Julia Crowley, MD, will see children in CHOP’s Congenital Hyperinsulinism Center.